OGA and Alzheimer disease: Here, we tested the hypothesis that globally increasing O-GlcNAcylation in TgF344-AD rats using the OGA inhibitor TMG for 3 months, beginning at 6 months of age, would reduce Aβ plaques, decrease glial cell reactivity, and lessen NA axon loss in the hilus of the DG measured at 9 months of age.